JP2011503233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503233A5 JP2011503233A5 JP2010535014A JP2010535014A JP2011503233A5 JP 2011503233 A5 JP2011503233 A5 JP 2011503233A5 JP 2010535014 A JP2010535014 A JP 2010535014A JP 2010535014 A JP2010535014 A JP 2010535014A JP 2011503233 A5 JP2011503233 A5 JP 2011503233A5
- Authority
- JP
- Japan
- Prior art keywords
- yloxy
- pyridin
- diazepan
- methanone
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- -1 cyclocyclobutyl Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 206010041349 Somnolence Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000032140 Sleepiness Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- QVUOERZYMAHRRW-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 QVUOERZYMAHRRW-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000001573 Cataplexy Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- VXAJSHFQQHNGQX-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclobutyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 VXAJSHFQQHNGQX-UHFFFAOYSA-N 0.000 claims 1
- YNZIFJAHDHVCJE-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclohexyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 YNZIFJAHDHVCJE-UHFFFAOYSA-N 0.000 claims 1
- ATMRCNUBMGDAJB-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclopentyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 ATMRCNUBMGDAJB-UHFFFAOYSA-N 0.000 claims 1
- JTJVOKQSNSXDSQ-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[5-(oxan-4-yloxy)pyridin-2-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)C=NC=1C(=O)N(CC1)CCCN1C1CCC1 JTJVOKQSNSXDSQ-UHFFFAOYSA-N 0.000 claims 1
- WERIDDXCKXMLPN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-ethylazepan-3-yl)oxypyridin-3-yl]methanone Chemical compound C1N(CC)CCCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 WERIDDXCKXMLPN-UHFFFAOYSA-N 0.000 claims 1
- UWCKCKPVQKWRLE-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-methylpiperidin-4-yl)oxypyridin-3-yl]methanone Chemical compound C1CN(C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 UWCKCKPVQKWRLE-UHFFFAOYSA-N 0.000 claims 1
- QIIMXKWOAINTGQ-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-methylpyrrolidin-3-yl)oxypyridin-3-yl]methanone Chemical compound C1N(C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 QIIMXKWOAINTGQ-UHFFFAOYSA-N 0.000 claims 1
- CIZGYGDRXHSNNY-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-propan-2-ylazepan-4-yl)oxypyridin-3-yl]methanone Chemical compound C1CN(C(C)C)CCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 CIZGYGDRXHSNNY-UHFFFAOYSA-N 0.000 claims 1
- OBURCTXWJHSPOX-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(cyclobutylmethoxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OCC2CCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 OBURCTXWJHSPOX-UHFFFAOYSA-N 0.000 claims 1
- VEXRDBRLGWUOJS-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(cyclopropylmethoxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OCC2CC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 VEXRDBRLGWUOJS-UHFFFAOYSA-N 0.000 claims 1
- OXXUXAYRUZNWAN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-2-yl]methanone Chemical compound C=1C=CC(OC2CCOCC2)=NC=1C(=O)N(CC1)CCCN1C1CCC1 OXXUXAYRUZNWAN-UHFFFAOYSA-N 0.000 claims 1
- NUYACTQCGLVCMC-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxepan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 NUYACTQCGLVCMC-UHFFFAOYSA-N 0.000 claims 1
- LRPQZEPPDZMKDA-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxepan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 LRPQZEPPDZMKDA-UHFFFAOYSA-N 0.000 claims 1
- BFJLVORPAXGFKY-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 BFJLVORPAXGFKY-UHFFFAOYSA-N 0.000 claims 1
- YWTLQMXBLFRANM-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thian-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCSCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 YWTLQMXBLFRANM-UHFFFAOYSA-N 0.000 claims 1
- CPBJQSTWGOQQPN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiepan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CSCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 CPBJQSTWGOQQPN-UHFFFAOYSA-N 0.000 claims 1
- XAEOEVMPYKYFCO-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiepan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCSCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 XAEOEVMPYKYFCO-UHFFFAOYSA-N 0.000 claims 1
- IDOPSVITNKOECG-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CSCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 IDOPSVITNKOECG-UHFFFAOYSA-N 0.000 claims 1
- MGCIMRQKRGCWIW-UHFFFAOYSA-N (4-cyclobutylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CCC1 MGCIMRQKRGCWIW-UHFFFAOYSA-N 0.000 claims 1
- ZAMBPCHSYIEQEW-UHFFFAOYSA-N (4-cyclopentyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCCC1 ZAMBPCHSYIEQEW-UHFFFAOYSA-N 0.000 claims 1
- HIJUMTVHMNNALA-UHFFFAOYSA-N (4-cyclopentylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CCCC1 HIJUMTVHMNNALA-UHFFFAOYSA-N 0.000 claims 1
- GDEYUSKKFOOEFV-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CC1 GDEYUSKKFOOEFV-UHFFFAOYSA-N 0.000 claims 1
- VRDXIGWWUIWIRM-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[6-(oxolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCC2)N=CC=1C(=O)N(CC1)CCCN1C1CC1 VRDXIGWWUIWIRM-UHFFFAOYSA-N 0.000 claims 1
- LBRUZEHUUYGSJN-UHFFFAOYSA-N (4-cyclopropylpiperazin-1-yl)-[6-(oxan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCCC2)N=CC=1C(=O)N(CC1)CCN1C1CC1 LBRUZEHUUYGSJN-UHFFFAOYSA-N 0.000 claims 1
- XOUOBAGFBFSLMB-UHFFFAOYSA-N (4-cyclopropylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CC1 XOUOBAGFBFSLMB-UHFFFAOYSA-N 0.000 claims 1
- GQSAFMNDDDSCJD-UHFFFAOYSA-N 1-[3-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxypyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 GQSAFMNDDDSCJD-UHFFFAOYSA-N 0.000 claims 1
- CYUFBNIXXRIJMO-UHFFFAOYSA-N 1-[4-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxyazepan-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 CYUFBNIXXRIJMO-UHFFFAOYSA-N 0.000 claims 1
- WRMDPNFCGVUCEJ-UHFFFAOYSA-N 1-[4-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxypiperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 WRMDPNFCGVUCEJ-UHFFFAOYSA-N 0.000 claims 1
- ZWEWUVQWWYKCEY-UHFFFAOYSA-N 3-cyclohexyloxy-6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2CCCCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 ZWEWUVQWWYKCEY-UHFFFAOYSA-N 0.000 claims 1
- HWIBZEXREFGUOK-UHFFFAOYSA-N 3-cyclopentyloxy-6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2CCCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 HWIBZEXREFGUOK-UHFFFAOYSA-N 0.000 claims 1
- NVXAPLQKZORNMX-UHFFFAOYSA-N 6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)-3-(oxolan-3-yloxy)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2COCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 NVXAPLQKZORNMX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- YTYZYBQMJSYXCS-UHFFFAOYSA-N [6-(oxan-4-yloxy)pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OC1CCOCC1 YTYZYBQMJSYXCS-UHFFFAOYSA-N 0.000 claims 1
- QVCDNGPZHDYLTF-UHFFFAOYSA-N [6-(oxan-4-yloxy)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OC1CCOCC1 QVCDNGPZHDYLTF-UHFFFAOYSA-N 0.000 claims 1
- AOAATJGNDYOJLI-UHFFFAOYSA-N [6-(oxolan-3-yloxy)pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OC1COCC1 AOAATJGNDYOJLI-UHFFFAOYSA-N 0.000 claims 1
- QFMMEHWYAXVVKG-UHFFFAOYSA-N [6-(oxolan-3-yloxy)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OC1COCC1 QFMMEHWYAXVVKG-UHFFFAOYSA-N 0.000 claims 1
- JOQCUMLLZBXYRU-UHFFFAOYSA-N [6-[(3-methyloxetan-3-yl)methoxy]pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OCC1(C)COC1 JOQCUMLLZBXYRU-UHFFFAOYSA-N 0.000 claims 1
- PSQBHHXUGLRPQZ-UHFFFAOYSA-N [6-[(3-methyloxetan-3-yl)methoxy]pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OCC1(C)COC1 PSQBHHXUGLRPQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003551 oxepanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001583 thiepanyl group Chemical group 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 0 C*1(CCN(*)CC1)C(C1=CC=C(*)**1)=O Chemical compound C*1(CCN(*)CC1)C(C1=CC=C(*)**1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98924607P | 2007-11-20 | 2007-11-20 | |
| US60/989,246 | 2007-11-20 | ||
| PCT/US2008/083764 WO2009067401A1 (en) | 2007-11-20 | 2008-11-17 | Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503233A JP2011503233A (ja) | 2011-01-27 |
| JP2011503233A5 true JP2011503233A5 (https=) | 2012-01-05 |
| JP5498390B2 JP5498390B2 (ja) | 2014-05-21 |
Family
ID=40297867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535014A Expired - Fee Related JP5498390B2 (ja) | 2007-11-20 | 2008-11-17 | ヒスタミンｈ３受容体のモジュレーターとしてのシクロアルキルオキシ−及びヘテロシクロアルキルオキシピリジン化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8883776B2 (https=) |
| EP (1) | EP2222664B1 (https=) |
| JP (1) | JP5498390B2 (https=) |
| KR (1) | KR101546712B1 (https=) |
| CN (2) | CN101868454A (https=) |
| AR (2) | AR069387A1 (https=) |
| AU (1) | AU2008326561B2 (https=) |
| BR (1) | BRPI0820481A2 (https=) |
| CA (1) | CA2706328C (https=) |
| CL (1) | CL2008003465A1 (https=) |
| CO (1) | CO6210700A2 (https=) |
| CR (1) | CR11529A (https=) |
| EA (1) | EA018582B1 (https=) |
| EC (1) | ECSP10010190A (https=) |
| MX (1) | MX2010005488A (https=) |
| MY (1) | MY158253A (https=) |
| NI (1) | NI201000086A (https=) |
| NZ (1) | NZ584998A (https=) |
| TW (1) | TWI491604B (https=) |
| UA (1) | UA103468C2 (https=) |
| WO (1) | WO2009067401A1 (https=) |
| ZA (1) | ZA201004334B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| TW200918527A (en) * | 2007-09-06 | 2009-05-01 | Glaxo Group Ltd | Piperazine derivative having affinity for the histamine H3 receptor |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| BRPI0913057A2 (pt) * | 2008-05-08 | 2015-10-13 | Evotec Ag | azetidinas e ciclobutanos como antagonistas de receptor de histamina h3 |
| PT3216784T (pt) | 2009-03-18 | 2019-04-01 | Janssen Pharmaceutica Nv | Processo para a preparação de moduladores do recetor h3 de histamina |
| MX2012003394A (es) * | 2009-09-21 | 2012-08-15 | Univ Vanderbilt | Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5. |
| LT2729130T (lt) | 2011-07-07 | 2018-01-10 | Janssen Sciences Ireland Uc | Darunaviro derinių kompozicijos |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE817911C (de) | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
| BE726551A (https=) | 1968-01-22 | 1969-06-16 | ||
| ES436109A1 (es) | 1974-04-04 | 1977-01-01 | Christiaens Sa A | Procedimiento para la preparacion de nuevos derivados de pi-ridina. |
| EP0089765A3 (en) | 1982-03-17 | 1984-05-23 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
| GB8311443D0 (en) | 1983-04-27 | 1983-06-02 | Smith Kline French Lab | Chemical compounds |
| GB8320505D0 (en) | 1983-07-29 | 1983-09-01 | Smith Kline French Lab | Chemical compounds |
| GB8332091D0 (en) | 1983-12-01 | 1984-01-11 | Smith Kline French Lab | Chemical compounds |
| JPS61149119A (ja) | 1984-12-22 | 1986-07-07 | 旭光学工業株式会社 | 検眼用試験枠 |
| US4792547A (en) | 1985-12-26 | 1988-12-20 | Hokuriku Pharmaceutical Co., Ltd. | Pyrazine-2-carboxamide derivatives useful in treating allergic disease |
| JPH0637595B2 (ja) | 1986-08-06 | 1994-05-18 | 日本ペイント株式会社 | 陰極電着塗料組成物 |
| GB9025828D0 (en) | 1990-11-28 | 1991-01-09 | Shell Int Research | Herbicidal carboxamide derivatives |
| JP3354271B2 (ja) | 1993-02-25 | 2002-12-09 | 三共株式会社 | ピリジルオキシアミド誘導体 |
| DE69628705T2 (de) | 1995-08-24 | 2004-05-13 | Basf Ag | Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide |
| DE69627709T2 (de) | 1995-12-28 | 2004-02-26 | Kureha Kagaku Kogyo K.K. | N-(unsubstituierte oder substituierte)-4-substituierte-6-(unsubstituierte oder substituierte)phenoxy-2-pyridincarboxamide oder -thiocarboxamide, verfahren zu deren herstellung sowie herbizide |
| TNSN97092A1 (ar) | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| ES2252004T3 (es) | 1999-05-21 | 2006-05-16 | Biovitrum Ab | Nuevos compuestos, su uso y preparacion. |
| US6399607B1 (en) | 1999-07-02 | 2002-06-04 | Research Foundation-State University Of New York | Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| JP2002322163A (ja) | 2001-04-20 | 2002-11-08 | Sumitomo Pharmaceut Co Ltd | ピペラジン誘導体 |
| BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| KR20040010713A (ko) | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| EP1421071B1 (en) | 2001-07-02 | 2009-11-18 | High Point Pharmaceuticals, LLC | Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| CA2463821A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| MXPA04004178A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| AU2003203148A1 (en) | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| GB0206219D0 (en) | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| AU2003226094A1 (en) | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| US20060052597A1 (en) | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| SI1558595T1 (sl) | 2002-10-23 | 2010-03-31 | Janssen Pharmaceutica Nv | Piperazinilni in diazapanilni benzamidi in benztioamidi |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| EP1642898B1 (en) | 2003-06-27 | 2013-03-27 | Msd K.K. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| DK1651615T3 (da) | 2003-07-29 | 2010-05-25 | High Point Pharmaceuticals Llc | Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander |
| WO2005023247A1 (en) | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
| GB0324159D0 (en) * | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| DE602005025222D1 (de) | 2004-03-31 | 2011-01-20 | Janssen Pharmaceutica Nv | Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors |
| AU2005230902A1 (en) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds as histamine H3-receptor ligands |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| KR101336106B1 (ko) * | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| MX2008008339A (es) | 2005-12-21 | 2008-09-03 | Schering Corp | Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3. |
| BRPI0709612A2 (pt) | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
| EA015555B1 (ru) | 2006-05-30 | 2011-08-30 | Янссен Фармацевтика Н.В. | Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора |
| JP2009542706A (ja) | 2006-06-29 | 2009-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体の置換ベンズアミドモジュレーター |
| EP2220045A1 (en) * | 2007-11-20 | 2010-08-25 | Janssen Pharmaceutica, N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
-
2008
- 2008-11-17 EA EA201070637A patent/EA018582B1/ru unknown
- 2008-11-17 UA UAA201007603A patent/UA103468C2/ru unknown
- 2008-11-17 MY MYPI2010002288A patent/MY158253A/en unknown
- 2008-11-17 CN CN200880117055A patent/CN101868454A/zh active Pending
- 2008-11-17 KR KR1020107013252A patent/KR101546712B1/ko not_active Expired - Fee Related
- 2008-11-17 BR BRPI0820481-0A patent/BRPI0820481A2/pt not_active IP Right Cessation
- 2008-11-17 WO PCT/US2008/083764 patent/WO2009067401A1/en not_active Ceased
- 2008-11-17 JP JP2010535014A patent/JP5498390B2/ja not_active Expired - Fee Related
- 2008-11-17 EP EP08852442.6A patent/EP2222664B1/en not_active Not-in-force
- 2008-11-17 AU AU2008326561A patent/AU2008326561B2/en not_active Ceased
- 2008-11-17 MX MX2010005488A patent/MX2010005488A/es active IP Right Grant
- 2008-11-17 CN CN201610094782.9A patent/CN105712977B/zh not_active Expired - Fee Related
- 2008-11-17 CA CA2706328A patent/CA2706328C/en not_active Expired - Fee Related
- 2008-11-17 US US12/272,268 patent/US8883776B2/en not_active Expired - Fee Related
- 2008-11-17 NZ NZ584998A patent/NZ584998A/xx not_active IP Right Cessation
- 2008-11-19 TW TW097144606A patent/TWI491604B/zh not_active IP Right Cessation
- 2008-11-20 CL CL2008003465A patent/CL2008003465A1/es unknown
- 2008-11-20 AR ARP080105055A patent/AR069387A1/es not_active Application Discontinuation
-
2010
- 2010-05-18 NI NI201000086A patent/NI201000086A/es unknown
- 2010-05-19 EC EC2010010190A patent/ECSP10010190A/es unknown
- 2010-05-20 CO CO10060285A patent/CO6210700A2/es active IP Right Grant
- 2010-06-18 ZA ZA2010/04334A patent/ZA201004334B/en unknown
- 2010-06-21 CR CR11529A patent/CR11529A/es not_active Application Discontinuation
-
2018
- 2018-02-14 AR ARP180100346A patent/AR110977A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503233A5 (https=) | ||
| HRP20192032T1 (hr) | Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina | |
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| JP2014526435A5 (https=) | ||
| JP2009541216A5 (https=) | ||
| JP2011500694A5 (https=) | ||
| JP2011500693A5 (https=) | ||
| JP2004527467A5 (https=) | ||
| RU2010119528A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях | |
| JP2011500696A5 (https=) | ||
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| CN1283183A (zh) | 具有mmp和tnf抑制活性的异羟肟酸和羧酸衍生物 | |
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| JP2011500697A5 (https=) | ||
| JP2007504229A5 (https=) | ||
| NO20083369L (no) | Anvendelse av substituert 2-imidazol av imidazolinderivater | |
| TWI731842B (zh) | 醛固酮合成酶抑制劑 | |
| KR20080103043A (ko) | 우울증 환자에게 있는 수면 장애의 치료를 위해 의도된 치료제를 수득하기 위한 아고멜라틴의 사용 | |
| WO2007002884A2 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| JP2015107945A (ja) | 神経新生に関する化合物及び医薬組成物 | |
| WO2014180165A1 (zh) | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 | |
| RU2010119530A (ru) | Замещенные n-фенилпирролидинилметилпирролидинамиды и их терапевтическое применение в качестве модуляторов рецептора н3 гистамина | |
| JP2015521642A5 (https=) | ||
| Jiang et al. | Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl) piperidin-4-yl) methoxy) pyridin-3-yl) isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine | |
| WO2009109493A3 (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists |